INDIAN BENCHMARK upbeat to begin with.
Tata
Power's board will deliberate on various fund raising options, including by way
of preferential issue of shares to institutional investors, on February 27.
FURTHER, Ranbaxy Labs
will be in focus after Japanese drugmaker Daiichi Sankyo Co Ltd said that its
Indian unit Ranbaxy Laboratories Ltd has suspended shipment of pharmaceutical
ingredients produced at its Toansa and Dewas plants. JP Associates
may be in action on reports of stake sale of cement plants.
Trend in FII flows: The FIIs
were net buyers of Rs.266cr in the cash segment on Monday while the
domestic institutional investors (DIIs) were net sellers
of Rs. 248cr, as per the provisional figures released by the NSE.